Scilex Holding (SCLX) Non Operating Investment Income (2025)
Scilex Holding (SCLX) posted quarterly Non Operating Investment Income of -$5.6 million for Q4 2025, down 167.5% quarter-over-quarter from $8.3 million in Q3 2025.
Scilex Holding (SCLX) Non Operating Investment Income (2025) Analysis & Trends
Scilex Holding's Non Operating Investment Income history runs 1 years deep, the most recent figure standing at -$5.6 million for Q4 2025.
- In Q4 2025, Non Operating Investment Income changed N/A year-over-year to -$5.6 million; the TTM figure through Dec 2025 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was $2.7 million, changed N/A from the prior year.
- Non Operating Investment Income for Q4 2025 stood at -$5.6 million, down from $8.3 million in the prior quarter.
- The five-year high for Non Operating Investment Income was $8.3 million in Q3 2025, with the low at -$5.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.59 Mn |
| Dec 31, 2025 | -5.59 Mn |
| Sep 30, 2025 | 8.28 Mn |
| Sep 30, 2025 | 8.28 Mn |